GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Santarus, Inc. (FRA:TW4A) » Definitions » Other Liabilities for Insurance Companies

Santarus, (FRA:TW4A) Other Liabilities for Insurance Companies


View and export this data going back to . Start your Free Trial

What is Santarus, Other Liabilities for Insurance Companies?

Other Liabilities for Insurance Companies only applies to insurance companies.


Santarus, (FRA:TW4A) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Santarus, Inc. (FRA:TW4A) » Definitions » Other Liabilities for Insurance Companies
Traded in Other Exchanges
N/A
Address
Santarus, Inc. was incorporated on December 6, 1996 as a California corporation and did not commence significant business activities until late 1998. On July 9, 2002, the Company reincorporated in the State of Delaware. The Company is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists. It sells brand prescription products primarily to pharmaceutical wholesalers, who in turn seek to distribute the products to retail pharmacies, mail order pharmacies, hospitals and other institutional customers. The Company's current commercial efforts are focused on five products: UCERIS, extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis and ZEGERID for the treatment of certain upper gastrointestinal disorders are promoted to gastroenterologists; GLUMETZA and CYCLOSET tablets, which are indicated as adjuncts to diet and exercise to improve glycemic control in adults with type 2 diabetes; and FENOGLIDE tablets, which is indicated as an adjunct to diet to reduce high cholesterol. The pipeline products include the investigational drug RUCONEST for treatment of acute attacks of hereditary angioedema.